Endocrine Society
Tirzepatide plus hormone replacement therapy boosts weight loss after menopause
Hormone replacement therapy combined with tirzepatide led to greater weight loss than tirzepatide alone, in this EHR data study of overweight/obese postmenopausal women, presented at the Endocrine Society’s 2025 annual meeting.
Study details. Researchers examined EHR data on 120 postmenopausal women on tirzepatide; 40 were on hormone replacement therapy, 80 were not. Median study duration: 18 months.
Results. Weight lost for women on the combination of tirzepatide plus menopausal hormone therapy was 17% vs. 14% on tirzepatide alone. Furthermore, 45% of patients on combined therapies achieved 20% or more weight loss vs. 18% of those not on hormone therapy.
Source:
(2025, July 12). Endocrine Society. Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss [Press Release]. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/castaneda-press-release